Marc Dionne
- Formation
- à venir
Aucune offre active
Autres opportunités de carrièreAucune étude clinique active
Autres études cliniques
- Axe principal
- Santé des populations et environnementale
- Adresse
- 2875, boulevard Laurier, Édifice Delta II, 6e étage, bureau 600
Québec (Québec)
CANADA G1V 2M2 - Téléphone
- +1 418-666-7000, poste 240
- Télécopieur
- +1 418-654-2776
- Courriel
- marc.dionne@inspq.qc.ca
Publications récentes (voir toutes les publications de ce chercheur)
Gilca V, Dionne M, Boulianne N, Murphy D, De Serres G. LONG-TERM IMMUNOGENICITY OF TWO PEDIATRIC DOSES OF COMBINED HEPATITIS A AND B OR MONOVALENT HEPATITIS B VACCINE IN 8 TO 10-YEAR-OLD CHILDREN AND THE EFFECT OF A CHALLENGE DOSE GIVEN SEVEN YEARS LATER. The Pediatric infectious disease journal,
2009. Epub
Gilca V, Sauvageau C, McNeil S, Gemmill IM, Dionne M, Dobson S, Ouakki M, Lavoie F, Duval B. Setting priorities for new vaccination programs by using public health officers and immunization managers opinions. Vaccine,
2008. 26: 4204-9
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet,
2007. 369: 2161-70
Hubert B, Gilca R, Dionne M. Infections à Clostridium difficile NAP1/027 : l’expérience du Québec Hygiènes,
2007. XV: 135-141
Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine,
2007. 25: 1121-5
McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine,
2007. 25: 3464-74
Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, Dionne M, Lorange M. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
2007. 44: 238-44
Beaulieu S, Couillard M, Bourgault AM, Claessens C, Côté R, De Wals P, Dionne M, Massé R. Avis scientifique sur le port du masque dans la communauté en situation de pandémie d'influenza Québec: Institut national de santé publique, 2007. 52 pages.
Guay M, Blackburn M, Pelletier A, Tremblay A, St-Hilaire C, Clément P, Clouâtre AM, Rousseau L, Landry M, St-Amand D, Dionne M. Étude sur les coûts et l'efficacité du programme de vaccination contre l'influenza au Québec Montréal, QC: Institut national de santé publique du Québec, 2007. 90 pages.
Boulianne N, Deceuninck G, Duval B, Lavoie F, Dionne M, Carsley J, Valiquette L, Rochette L, De Serres G. [Why are some children incompletely vaccinated at the age of 2?]
Canadian journal of public health. Revue canadienne de sante publique,
2003. 94: 218-23
